The Year’s Two Largest Conjugate Deals Were Not ADCs, and Not Cancer Drugs
Buyers stopped paying for conjugate drugs and started paying for conjugate chemistry. The year’s two biggest cheques bought neither an ADC nor a cancer drug.
license agreeements
DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead
Every July metric fell except the median and the cash share. Vertex paid a 102% premium for Crinetics and carried a fifth of the month alone.
DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B
DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A came back big, and wrote the cheque in cash M&A value rose 96% to $188 billion in the first half of 2026 and upfront payments jumped 72%, as acquirers paid … Read more
AlzeCure Pharma Secures a $2.2B QuantumCell Deal for Its NeuroRestore Platform
AlzeCure Pharma has found a partner for its Alzheimer’s program, and the numbers attached to the deal are eye-catching, though not all of them in the way the headline suggests. The Swedish biotech said on July 1 that it has signed an out-licensing and collaboration agreement with QuantumCell, a Danish “tech-enabled” biotech, handing over global … Read more
Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
DealFlow: Biopharma Deals This Week June 22–28, 2026
DealFlow Weekly — Wk 26 · 2026 · Synopulse DealFlow WeeklyOn a deep pine background, a faint network of the week’s thirty-five deals fades in while a gold deal line draws across and five gold molecular-ring nodes bloom along it, beside the DealFlow Weekly wordmark and the tagline a weekly readout from Synopulse. SYNOPULSE — … Read more
Pfizer and Innovent Strike $10.5B Oncology Collaboration
Pfizer has signed one of the year’s largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China’s Innovent Biologics.
February 2026 Deal Report: Five Signals from $53B in Activity
February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
Lilly taps InduPro’s proximity-guided platform in up to $950M oncology deal
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.